[ad_1]
Radnor, Pennsylvania, June 16, 2021 (Global News Agency) – The law firm of Kessler Topaz Meltzer & Check, LLP reminded ChemoCentryx, Inc. (NASDAQ:China Chengxin International) (“ChemoCentryx”) investor who has represented a person who purchased or acquired ChemoCentryx common stock in a securities fraud class action against ChemoCentryx in the Northern District of California November 26, 2019 to May 6, 2021, Included (“Class Hours”).
Deadline for lead plaintiff: July 6, 2021
contact:
James Marlow, Esq. (484) 270-1453
Adrienne Bell, Esq. (484) 270-1435
Toll Free (844) 887-9500
ChemoCentryx is a biopharmaceutical company focused on the development and commercialization of new drugs for inflammatory diseases, autoimmune diseases and cancer. The main drug candidate of ChemoCentryx is avacopan.
The complaint stated that during the entire class action period, the defendant misrepresented and/or failed to disclose to investors: (1) ChemoCentryx was fundamentally flawed in the design of the ADVOCATE Phase III trial, which led to the interpretability and ability of the trial data Questions to determine the clinically significant benefits of avacopan and its role in the treatment of ANCA-related vasculitis; (2) The results of the ADVOCATE trial pose serious safety issues for avacopan; (3) These issues have implications for ChemoCentryx’s new drug application (“NDA ”) #214487 The feasibility of avacopan for the treatment of ANCA-related vasculitis raises major questions. Therefore, the defendant’s statements regarding the ADVOCATE trial design, effectiveness and safety results were materially false and misleading at all relevant times.
ChemoCentryx investors can, No later than July 6, 2021, Seeking to be appointed as the chief plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other lawyers, or can choose to do nothing and remain absent class members. The lead plaintiff is the representative party who directs litigation on behalf of all class members. In order to be appointed as the lead plaintiff, the court must determine that the claim of a class member is a typical representative of the claims of other class members and that the class member will fully represent the class. Your ability to share any recovery is not affected by the decision whether to serve as the lead plaintiff.
Kessler Topaz Meltzer & Check, LLP is suing class actions involving securities fraud, breach of fiduciary duties, and other violations of state and federal laws in state and federal courts across the country. Kessler Topaz Meltzer & Check, LLP is the driving force of corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors in the United States and around the world. The company represents investors, consumers, and whistleblowers (private citizens who report fraud against the government and share the recovery of government funds). The complaint in this lawsuit was not filed by Kessler Topaz Meltzer & Check, LLP.For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
contact:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, Pennsylvania 19087
(844) 887-9500 (toll free)
info@ktmc.com
[ad_2]
Source link
